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Abstract DNA topoisomerase I from Mycobacterium smegma-
tis unlike many other type I topoisomerases is a site specific
DNA binding protein. We have investigated the sequence specific
DNA binding characteristics of the enzyme using specific
oligonucleotides of varied length. DNA binding, oligonucleotide
competition and covalent complex assays show that the substrate
length requirement for interaction is much longer (V20
nucleotides) in contrast to short length substrates (eight
nucleotides) reported for Escherichia coli topoisomerase I and
III. P1 nuclease and KMnO4 footprinting experiments indicate a
large protected region spanning about 20 nucleotides upstream
and 2^3 nucleotides downstream of the cleavage site. Binding
characteristics indicate that the enzyme interacts efficiently with
both single-stranded and double-stranded substrates containing
strong topoisomerase I sites (STS), a unique property not shared
by any other type I topoisomerase. The oligonucleotides
containing STS effectively inhibit the M. smegmatis topoisome-
rase I DNA relaxation activity. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Type I DNA topoisomerases [1,2] alter the topology of
DNA by transient breakage and resealing of the DNA, while
passing the intact strand through the enzyme-operated DNA
gate. Type I topoisomerases along with the type II enzymes
play a role in maintaining the superhelical density of the cel-
lular DNA [3] and solve the topological constraints in DNA
arising due to di¡erent macromolecular events [4]. Thus, top-
oisomerase I has a vital physiological role. Although these
enzymes have been studied in great detail from many systems,
several questions remain unanswered as to how topoisomer-
ases interact with DNA to carry out their functions in the cell.
The type I topoisomerases in general are not considered to be
sequence speci¢c DNA binding proteins. However, few mem-
bers show some degree of sequence speci¢city [5^7]. Further,
in accordance with their function, many of them are known to
recognize structures on DNA rather than speci¢c sequences.
Escherichia coli topoisomerase I and yeast topoisomerase III
bind to underwound but not to overwound DNA and hence
capable of relaxation of negatively supercoiled DNA. Eukary-
otic type I DNA topoisomerases, in contrast, can relax both
negatively and positively supercoiled DNA with nearly equal
e⁄ciency [8]. Eukaryotic topoisomerases I and II recognize
DNA sites possessing intrinsic curvatures [9^11]. Thus, in ad-
dition to the conventional classi¢cation of topoisomerases as
type I and II based on reaction mechanistics, they have been
grouped with respect to the conformation of the substrate
DNA [12]. The ¢rst group includes enzymes which bind to
duplex DNA and the second consists of enzymes which pref-
erentially bind to single-stranded DNA [12]. All known type
II topoisomerases of both prokaryotic and eukaryotic origin
and eukaryotic type I DNA topoisomerases could be consid-
ered to belong to the former group; bacterial type I topoiso-
merase and archaebacterial reverse gyrase would ¢t into the
second group. While the ¢rst group of enzymes are known to
exhibit a somewhat complex sequence recognition pattern, the
cleavage speci¢city of the latter group is quite simple. The
presence of a cytosine four nucleotides away on the 5P-side
of the nick (position 34) is observed in majority of the sites
mapped for topoisomerase I from E. coli [13], Micrococcus
luteus [14] and archaebacterial reverse gyrase [12]. E. coli top-
oisomerase I can cleave single-stranded oligonucleotides as
short as seven bases in length [15]. From these studies, it
appears that a normal reaction of this enzyme may involve
binding to only a short stretch of DNA [16].
We have characterized DNA topoisomerase I from Myco-
bacterium smegmatis. In many characteristics the enzyme is
similar to other prokaryotic type I topoisomerases [17]. How-
ever, in contrast to E. coli topoisomerase I, fewer cysteines are
present in the mycobacterial enzyme and they do not form
Zn2 co-ordination for DNA binding [18]. These results in-
dicate a di¡erent mode of interaction of the enzyme with
DNA and prompted us to study the DNA binding character-
istics. We have mapped strong topoisomerase sites (STS) in
linear fragments and also in supercoiled plasmids containing
genomic sequences from M. smegmatis [19,20]. Synthetic oli-
gonucleotides having the consensus sequence were used as
substrates for DNA binding and cleavage reactions of the
enzyme [20].
In this manuscript, we have carried out detailed studies on
site speci¢c interaction of the M. smegmatis topoisomerase I
with oligonucleotides having the recognition sequence. The
enzyme exhibits certain unique features. E⁄cient interaction
with both single- and double-stranded DNA and requirement
for larger minimal substrate by the M. smegmatis topoisomer-
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ase I are the key features. In addition, STS containing oligo-
nucleotides inhibit DNA relaxation activity of the enzyme.
2. Materials and methods
2.1. Enzymes and nucleic acids
M. smegmatis topoisomerase I was puri¢ed to apparent homogene-
ity as described previously [18]. Restriction endonucleases and T4
polynucleotide kinase were purchased from Boehringer Mannheim
and Gibco BRL. P1 nuclease and the NAP 10 gel ¢ltration columns
were obtained from Pharmacia. Supercoiled pUC19 DNA was puri-
¢ed by standard procedures [21]. DNA oligonucleotides were obtained
from Bangalore Genei (Pvt.) Ltd., Bangalore, India. Radioisotopes
([Q-32P]ATP and [K-32P]dATP) were purchased from Amersham
Corp. Other chemicals used were from Gibco BRL. The oligonucleo-
tides used in this study are as follows: 5P-TATTGGGCGCTCTTCC-
GCTTCCTCGCTCACTG-3P (32 mer); 5P-TTGGGCGCTCTTCCG-
CTTCCTCGCTCAC-3P (28 mer); 5P-GGGCGCTCTTCCGCTTCC-
TCGCTC-3P (24 mer); 5P-GCGCTCTTCCGCTTCCTCGC-3P (20
mer); 5P-GCTCTTCCGCTTCCTC-3P (16 mer); 5P-TCTTCCGCTT-
CC-3P (12 mer). The respective complementary strands were also used
in some of the experiments. Double-stranded oligonucleotides were
prepared by mixing equimolar top (oligonucleotide having STS) and
bottom (complementary to the top strand) strand oligonucleotides,
and then incubating at 90‡C for 5 min. The mixtures were then slowly
cooled to room temperature. Annealing of the oligonucleotides was
assessed by resolving the samples on a native polyacrylamide gel elec-
trophoresis (PAGE) along with the single-stranded oligonucleotides.
2.2. Radiolabeling of oligonucleotides
Oligonucleotides were 5P-end-labeled using [Q-32P]ATP (speci¢c ac-
tivity, 6000 Ci/mmol) and bacteriophage T4 polynucleotide kinase as
per manufacturer’s recommendations. The labeled oligonucleotides
(speci¢c activity of labeling was approximately 108 counts per minute
(cpm)/Wg of DNA) were puri¢ed using Sephadex G-25 spin columns.
2.3. Nuclease P1 protection assay
Reactions (10 Wl) contained assay bu¡er without Mg2 (40 mM
Tris^HCl pH 8.0, 20 mM NaCl) and 200 fmol of radiolabeled oligo-
nucleotide. M. smegmatis topoisomerase I was added to the above
reaction mix and incubated for 5 min at 37‡C followed by incubation
with 0.003 U of P1 nuclease for 10 min at 37‡C. The reactions were
terminated by the addition of EDTA to a ¢nal concentration of 10
mM, and heat-denatured for 5 min at 90‡C after addition of the
loading dye (45% formamide, 0.025% bromophenol blue, 0.025% xy-
lene cyanol). The products were separated by electrophoresis through
a 15% PAGE.
2.4. KMnO4 footprinting
Oligonucleotides (32 mer top strand, 100 fmol, 105 cpm) were
incubated with topoisomerase I in 10 Wl assay bu¡er (without
Mg2) on ice for 10 min. Freshly prepared KMnO4 (250 nM ¢nal
concentration) was added to the reaction mix and incubated at 37‡C
for 30 s. The reactions were terminated by the addition of 7.5 Wl of L-
mercaptoethanol (40 mM), 80 Wl of sodium acetate (0.375 M) and 50
Wg/ml yeast total RNA. The oligonucleotides were ethanol-precipi-
tated twice, washed with 70% ethanol and suspended in 100 Wl of
1 M piperidine. Samples were heated at 90‡C for 30 min, lyophilized,
resuspended in 10 Wl of formamide loading dye and analyzed on
15% polyacrylamide^8 M urea gels. The control samples were treated
in the same way except that KMnO4 was not added to the reaction
mix.
2.5. Electrophoretic mobility shift assay (EMSA)
Non-covalent enzyme^DNA complexes were formed using 40 mM
Tris^HCl pH 8.0, 20 mM NaCl, 1 mM EDTA, 10 fmol of radiola-
beled oligonucleotide and varying amounts of M. smegmatis topoiso-
merase I by incubating on ice for 5 min. The products were separated
through a 5% non-denaturing PAGE (30:0.8). The gels were electro-
phoresed at 100 V for 1.5 h at 4‡C, dried and subjected to autora-
diography.
2.6. Gel mobility shift assay for the detection of covalent complex
Radiolabeled 65 bp DNA fragment [19] or di¡erent duplex oligo-
nucleotides listed above were incubated with M. smegmatis topoiso-
merase I at 37‡C for 15 min. The covalent complexes were arrested by
adding 10 mM NaOH. This assay mixture contained 250 fmol of
unlabeled oligonucleotide wherever indicated. The products were sep-
arated on a 10% PAGE with 0.5UTBE as the running bu¡er. The gels
were electrophoresed at 150 V for 2 h at room temperature, dried and
autoradiographed.
Fig. 1. Topoisomerase I footprinting. Footprinting reactions were performed as described in Section 2. The reaction products were resolved
through a 15% polyacrylamide gel containing 8 M urea. A: P1 nuclease protection: substrate DNA alone (lane 1), 0.1 pmol (lane 3), 0.25
pmol (lane 4), 0.5 pmol (lane 5), 1.0 pmol (lane 6) or 2 pmol (lane 7) of topoisomerase I and 0.003 U of P1 nuclease. Lanes 2 and 8 are the
P1 nuclease digested (0.003 U) 32 mer oligonucleotide. B: KMnO4 footprint: 32 mer oligonucleotide (lane 1) was treated with 25 nM KMnO4
in absence (lane 2) and in presence (lane 3) of 1 pmol of topoisomerase I. Cleavage product (indicated as P) is obtained from the 32 mer (lane
4). Maxam-Gilbert G reaction of the 32 mer is indicated.
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2.7. DNA relaxation assay
The reaction mixture contained 40 mM Tris^HCl pH 8.0, 5 mM
MgCl2, 20 mM NaCl, 0.33 pmol of pUC19 negatively supercoiled
DNA and 1 U of M. smegmatis topoisomerase I. Reaction mixes
were incubated at 37‡C for 15 min, stopped with 0.5% sodium dodecyl
sulfate and samples were separated on a 1.2% agarose gel. The DNA
was visualized by ethidium bromide staining.
3. Results
3.1. Topoisomerase I footprint on substrate DNA
The interaction of M. smegmatis topoisomerase I with its
binding site was analyzed by footprinting experiments using
32 mer oligonucleotides. Footprinting reactions were carried
out using P1 nuclease and KMnO4 as probes (Fig. 1A,B).
With higher amounts of topoisomerase, a large protected re-
gion was observed when probed with P1 nuclease. The enzyme
protects almost the entire 32 mer oligonucleotide (Fig. 1A,
lane 7). The results with KMnO4 footprinting show two pro-
tected regions which are located within the P1 nuclease foot-
print (Fig. 1B). These results demonstrate that the enzyme
binds a large stretch of DNA wherein cleavage site is located
towards the end of the protected region.
3.2. Minimal substrate required for binding
In order to assess the minimal length of DNA required for
topoisomerase I binding, STS containing oligonucleotides of
varied length were used (see Section 2). Binding was assessed
by the formation of the non-covalent complex between the
topoisomerase I and oligonucleotides and resolved by a native
PAGE (Fig. 2A,B). Non-covalent binding decreases with the
decreasing length of the oligonucleotides for both single- and
double-stranded substrates. While the 32, 28, 24 and 20 mer
single-stranded oligonucleotides (top strand) form the en-
zyme^DNA complex, only the 32 mer and 28 mer duplex
oligonucleotides show the complex formation. The ine⁄cient
binding of the enzyme to shorter oligonucleotides could be
due to rapid dissociation of the enzyme as a result of insu⁄-
cient contacts with DNA in agreement with footprinting re-
sults. Single-stranded oligonucleotides having STS seem to be
relatively better substrates for enzyme binding. Bottom strand
oligonucleotides (oligonucleotides without STS sequence) do
not form such complexes re£ecting the importance of the
presence of STS.
3.3. Covalent complex formation with duplex oligonucleotides
Ability of the enzyme to interact with the substrate was
assessed by arresting the DNA^protein covalent intermediate
of the reaction. This experiment would also reveal the mini-
mum length of the double-stranded DNA required for the ¢rst
transesteri¢cation reaction. The 32 and 28 mer duplex oligo-
nucleotides formed covalent complexes under the reaction
conditions (Fig. 3). The complex formation is weaker with
28 mer and hardly detectable with 24 mer. No detectable
complex was observed with the smaller duplex oligonucleoti-
des (Fig. 3).
3.4. Competition assay with the top and bottom strand
oligonucleotides
Minimum substrate length requirement and site speci¢c in-
teraction of the enzyme was demonstrated by a competition
assay. An end-¢lled 65 bp fragment of pUC19 having STS for
the M. smegmatis topoisomerase I [19] was used as a substrate
for covalent complex formation. Unlabeled top strand or bot-
tom strand oligonucleotides of di¡erent sizes were used as
Fig. 2. Binding of topoisomerase I to single- and double-stranded
oligonucleotides. EMSA was performed using (A) single- and (B)
double-stranded 32, 28, 24, 20 and 16 mer oligonucleotides (100
fmol each). The oligonucleotides were incubated in the absence
(lanes 1, 3, 5, 7 and 9) or in 1 pmol (lanes 2, 4, 6, 8 and 10) of top-
oisomerase I, respectively. The complexes were resolved through a
5% polyacrylamide gel at 4‡C. The position of the topoisomerase I^
oligonucleotide non-covalent complex is indicated.
Fig. 3. Minimum substrate length required for covalent complex
formation by M. smegmatis topoisomerase I. Double-stranded oligo-
nucleotides were incubated in the absence (lane 1) or in 1 pmol
(lane 2) and 2 pmol (lane 3) of topoisomerase I and complexes were
trapped with alkali. The samples were processed as described in Sec-
tion 2. Lengths of the oligonucleotides are indicated.
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competitor substrates. Amongst the top strand oligonucleoti-
des, the 32 mer competes e¡ectively with the 65 bp fragment
for complex formation (Fig. 4A, lane 3). Competition is also
seen with the 28 and 24 mers, albeit to a lesser extent. In
contrast, the 20, 16 and 12 mer oligonucleotides having STS
do not seem to a¡ect considerably the covalent complex for-
mation. When the bottom strand oligonucleotides were used
as competitors, complex formation was una¡ected irrespective
of the size of the oligonucleotides (Fig. 4B, lanes 2^5). These
results highlight the importance of presence of STS in the
oligonucleotides as well as the requirement of minimal sub-
strate length for the interaction of topoisomerase I with DNA.
3.5. Inhibition of DNA relaxation activity of topoisomerase I
by oligonucleotides
Above results indicate that oligonucleotides containing STS
should be e¡ective inhibitors for overall reaction of the en-
zyme. This is directly demonstrated by using the top strand
oligonucleotides containing STS as inhibitors of topoisomer-
ase I catalyzed relaxation of negatively supercoiled DNA. A
representative set of data is shown in Fig. 5. Both 32 mer and
28 mer oligonucleotides inhibit the DNA relaxation activity in
a 1:0.5 molar ratio (plasmid:oligonucleotide). In contrast, the
32 mer complementary strand oligonucleotide (without the
STS) does not inhibit the relaxation activity of the enzyme
even at a 100-fold excess concentration (Fig. 5B, lane 12).
The summary of the DNA relaxation inhibition data is pre-
sented in Fig. 5C. With shorter oligonucleotides, higher con-
centrations were required for inhibition of the DNA relaxa-
tion activity of the enzyme. These results are in agreement
with the competition, binding and covalent complex assays.
The above experiments while demonstrating the e¡ectiveness
of the oligonucleotides as inhibitors, further substantiate the
minimal substrate length requirement for the enzyme.
4. Discussion
We have probed the site speci¢c interaction of M. smegma-
tis topoisomerase I at its cognate site. Minimum substrate
length needed for binding and subsequent reaction is deter-
mined which is considerably larger amongst all known type
IA topoisomerases. Further, oligonucleotides having STS
were shown to inhibit DNA relaxation activity of the enzyme.
Fig. 4. Competition for covalent complex formation. End-labeled 65
bp DNA fragment (100 fmol) was used as the substrate for covalent
complex formation with 1 pmol of topoisomerase I and the complex
was arrested with NaOH as described earlier [19] and in Section 2.
A: Competition assay with top strand oligonucleotides. 1 pmol of
unlabeled 32, 28, 24, 20, 16 and 12 mer oligonucleotides containing
STS were used as competitors (lanes 3^8). Lane 1: no enzyme, lane
2: no competitor. B: E¡ect of bottom strand oligonucleotides. Lane
1: no competitor, 1.0 pmol of unlabeled 32, 28, 24 and 20 mer oli-
gonucleotides lacking the STS (lanes 2^5) were used as competitors,
respectively.
Fig. 5. Inhibition of topoisomerase I catalyzed DNA relaxation by
the STS containing oligonucleotides. A: The oligonucleotides (see
Section 2) used for assessing the inhibition of relaxation activity are
illustrated. Thick line represents the position of STS within the oli-
gonucleotides. B: DNA relaxation activity: DNA relaxation assay
was carried out using pUC19 DNA (0.33 pmol) with 2 ng of topoi-
somerase I and reaction products were resolved as described in Sec-
tion 2. Lane 1 is supercoiled pUC19 and lane 2 shows the relaxa-
tion reaction. The length of the oligonucleotides and the molar
ratios with respect to pUC19 are indicated. T and B refer to top
and bottom strands, respectively. C: Summary of inhibition data:
percentage inhibition of relaxation reaction by the oligonucleotides
is depicted.
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E. coli topoisomerase I or III were shown to e⁄ciently react
with 7^8 nucleotide long single-stranded oligonucleotides
[15,22] while even a 20 mer is a relatively poor substrate for
the enzyme from M. smegmatis. These results suggest an elab-
orate, more complex interaction of the enzyme with the sub-
strate DNA. Large protected region in footprint analysis sup-
ports this view. Inability of smaller oligonucleotides to inhibit
relaxation activity together with other experiments presented
in this report further substantiate this point. Another impor-
tant property of the mycobacterial topoisomerase emerging
from these studies is the e⁄cient interaction of the enzyme
with both single- and double-stranded oligonucleotides having
recognition sequences. E. coli topoisomerase III [22] is known
to interact site speci¢cally with single-stranded DNA. In con-
trast, eukaryotic enzymes (type IB) recognize duplex DNA as
substrates [23,24]. It would be of interest to decipher the mo-
lecular basis of distinct recognition pattern exhibited by M.
smegmatis enzyme.
Site speci¢c, high a⁄nity DNA binding proteins generally
recognize symmetric sequences. However, the STS of M.
smegmatis enzyme does not show any symmetry. The enzy-
me’s mode of interaction could be asymmetric as well. The
data with di¡erent length DNA substrates and KMnO4 foot-
printing indicate that the enzyme interacts asymmetrically
with DNA relative to its site of cleavage. The cleavage site
is located towards the 3P-end of the protected region. The
asymmetric sequence recognition pattern of the enzyme is
similar to that of topoisomerase III of E. coli [22].
A parallel can be drawn in the behavior of M. smegmatis
and human topoisomerase I in this regard. Human topoiso-
merase I is also a site speci¢c DNA binding protein and its
activity has been shown to be inhibited by speci¢c oligonu-
cleotides [25]. E⁄cient, speci¢c inhibition of the enzyme ac-
tivity is one of the remarkable features presented in this paper.
Only the oligonucleotides having the certain length and con-
taining recognition sequence serve as e¡ective inhibitors of the
enzyme. The results indicate that the oligonucleotides bind
and squelch away the enzyme molecules essentially denying
access to the supercoiled substrates.
Thus, the interaction of M. smegmatis topoisomerase I at its
STS has certain distinctive features. While the unique charac-
teristics re£ect the functional requirement, they open up ave-
nues to address reaction mechanistics and explore therapeutic
potential. Although topoisomerase I from prokaryotes plays a
central role in maintaining homeostatic balance of superhelic-
ity of the genome and thus in£uences the essential functions,
no inhibitor for the enzyme has been identi¢ed. Detailed
structure^function studies with both the enzyme and the sub-
strate DNA could form the basis for the design of inhibitors
for therapeutic and scienti¢c applications.
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